Published in Hepatology on April 01, 2005
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med (2010) 2.00
Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab (2011) 1.99
Leptin and the central nervous system control of glucose metabolism. Physiol Rev (2011) 1.94
Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology (2008) 1.76
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov (2012) 1.63
Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology (2008) 1.49
Leptin in human physiology and therapeutics. Front Neuroendocrinol (2010) 1.46
Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism (2007) 1.40
Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol (2010) 1.34
Adipocytokines and liver disease. J Gastroenterol (2008) 1.25
Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract (2011) 1.23
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev (2013) 1.10
Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab (2011) 1.04
Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab (2007) 1.03
Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2010) 1.03
Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab (2016) 1.00
Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95
Role of leptin resistance in the development of obesity in older patients. Clin Interv Aging (2013) 0.90
Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice. Am J Pathol (2012) 0.88
Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease. Wien Klin Wochenschr (2010) 0.87
Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab (2009) 0.86
New pharmacological perspectives for the leptin receptor in the treatment of obesity. Front Endocrinol (Lausanne) (2014) 0.86
Leptin in relation to the lipodystrophy-associated metabolic syndrome. Diabetes Metab J (2012) 0.85
Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm Res Paediatr (2012) 0.83
Syndromic insulin resistance: models for the therapeutic basis of the metabolic syndrome and other targets of insulin resistance. Endocr Pract (2012) 0.83
Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J Clin Endocrinol Metab (2014) 0.83
Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther (2011) 0.83
Leptin in the liver: a toxic or beneficial mix? Cell Metab (2012) 0.83
Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol (2015) 0.83
Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Sci OA (2015) 0.81
Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD. Diabetes (2016) 0.81
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab (2016) 0.80
Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol (2013) 0.80
Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Endocrine (2014) 0.79
New advances in the treatment of generalized lipodystrophy: role of metreleptin. Ther Clin Risk Manag (2015) 0.79
Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol (2016) 0.79
Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy. Diabetes Care (2014) 0.78
A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice. FASEB J (2017) 0.78
Role of CYP2E1 in mitochondrial dysfunction and hepatic tissue injury in alcoholic and non-alcoholic diseases. Curr Mol Pharmacol (2015) 0.77
Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals. Int J Endocrinol (2010) 0.76
Benefits of leptin therapy in HIV patients. Indian J Endocrinol Metab (2012) 0.76
Leptin and its emerging role in children and adolescents. Clin Pediatr Endocrinol (2006) 0.75
Berardinelli-Seip syndrome: highlight of treatment challenge. BMJ Case Rep (2013) 0.75
Metreleptin Treatment in Three Patients with Generalized Lipodystrophy. Clin Med Insights Case Rep (2017) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Leptin-replacement therapy for lipodystrophy. N Engl J Med (2002) 7.78
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest (2002) 5.83
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest (2002) 4.75
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
The use of U-500 in patients with extreme insulin resistance. Diabetes Care (2005) 2.68
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest (2009) 2.53
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest (2003) 2.42
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A (2004) 2.41
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Diagnostic accuracy of laparoscopy, magnetic resonance imaging, and histopathologic examination for the detection of endometriosis. Fertil Steril (2003) 2.00
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol (2008) 1.95
Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) (2002) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 1.91
Autoimmune forms of hypoglycemia. Medicine (Baltimore) (2009) 1.90
Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes (2005) 1.89
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract (2009) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat (2006) 1.75
Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab (2004) 1.73
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab (2006) 1.68
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol (2008) 1.67
A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog (2006) 1.66
Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab (2003) 1.65
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) (2004) 1.62
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer (2008) 1.62
Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab (2009) 1.62
Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation (2006) 1.61
Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab (2004) 1.61
Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol (2007) 1.61